Dyadic International, Inc., a global biotechnology company, has announced a proposed public offering of its common stock. The offering will be managed by Craig-Hallum Capital Group LLC, serving as the sole managing underwriter. Although the specifics of the offering, such as its size and terms, are still subject to market conditions, the company plans to utilize the net proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The securities will be offered under an effective shelf registration statement filed with the SEC. Further details will be available in a final prospectus supplement to be filed with the SEC.